CommercialCoverageMedium impact
Clarification on the coverage of Meningococcal (Groups A, C, W, and Y) conjugate vaccines for Commercial Members (Retroactively Effective to November 18, 2024)
Independence Blue Cross·Family Medicine, Internal Medicine, Pediatrics +1 more·News & Announcements
Effective date
Nov 18, 2024
We identified it
Jun 19, 2026
Summary
This policy provides clarification on coverage of Meningococcal (Groups A, C, W, and Y) conjugate vaccines for commercial insurance members. The clarification is retroactive to November 18, 2024, meaning any claims or coverage decisions from that date forward should follow the updated guidance.
Action Required
Immediately: Billing team should review any Meningococcal conjugate vaccine claims submitted since November 18, 2024 for commercial patients. Access the full policy details at the provided URL to understand specific coverage criteria. Resubmit any previously denied claims that now meet the clarified coverage requirements. Update billing procedures for future Meningococcal vaccine administration based on the new coverage guidelines.